| Literature DB >> 35885599 |
Mohd Saleem1, Azharuddin Sajid Syed Khaja1, Ashfaque Hossain2, Fahaad Alenazi3, Kamaleldin B Said1, Soha Abdallah Moursi1, Homoud Abdulmohsin Almalaq4, Hamza Mohamed5, Ehab Rakha6,7, Sunit Kumar Mishra8.
Abstract
Catheter-associated urinary tract infections (CAUTIs) are some of the most common hospital-acquired infections (HAIs). Prolonged hospitalization, invasive devices such as catheters, and irrational use of antimicrobial agents are believed to be the major causes of high rates of HAIs. Infections such as pyelonephritis, urethritis, cystitis, and prostatitis are the main concerns in catheterized ICU patients. In these cases, Gram-negative bacteria are the most common bacteria. The present study was undertaken to determine the frequency, antibiograms, disease pattern, and risk factors involved in providing an advocacy recommendation to prevent CAUTI. A total of 1078 patients were admitted to the hospital ICU, out of which healthcare-associated infection was reported in 316 patients. CAUTI was reported only in 70 patients. Klebsiella pneumoniae (20%) was the predominant isolate, with Serratia (3%) and Providencia (3%) species being the least common isolates in this study. The present study provides CAUTI incidence rates in a tertiary care hospital in Hail, Saudi Arabia. Furthermore, information on the risk factors of common associated CAUTI causative organisms and their antibiogram patterns are also presented. This study provides vital information that can be used to formulate an effective antibiotic stewardship program that can be implemented throughout the kingdom.Entities:
Keywords: Klebsiella pneumoniae; Proteus mirabilis; Pseudomonas aeruginosa; antibiogram; catheter-associated urinary tract infection (CAUTI); hospital-acquired infections
Year: 2022 PMID: 35885599 PMCID: PMC9322978 DOI: 10.3390/diagnostics12071695
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Age- and gender-specific frequency of CAUTI in the study participants.
| Age Group (Years) | Number of Patients | Percentage (%) |
|---|---|---|
| 20–30 | 5 | 7 |
| 30–40 | 2 | 3 |
| 40–50 | 5 | 7 |
| 50–60 | 12 | 17 |
| 60–70 | 16 | 23 |
| 70–80 | 21 | 30 |
| 80–90 | 9 | 13 |
|
| ||
| Male | 37 | 53 |
| Female | 33 | 47 |
|
| ||
| Underweight | 11 | 16 |
| Normal weight | 19 | 27 |
| Overweight | 28 | 40 |
| Obese | 12 | 17 |
Figure 1Gender-specific distribution of patients with CAUTI in the study participants.
Clinical characteristics of patients with CAUTI in the study participants.
| Patient Characteristics | Type of Catheter ( | Percentage (%) |
|---|---|---|
| Urethral type | 51 | 73 |
| Suprapubic type | 19 | 27 |
|
| ||
| 14 Fr | 16 | 23 |
| 16 Fr | 42 | 60 |
| 18 Fr | 12 | 17 |
|
| ||
| 0–14 | 13 | 18.5 |
| 15–30 | 20 | 28.5 |
| >31 | 37 | 53 |
|
| ||
| Urine retention | 2 | 3 |
| Urethral stricture | 9 | 13 |
| Benign prostatic hyperplasia | 37 | 53 |
| Urinary incontinence | 20 | 27 |
| Others | 2 | 3 |
|
| ||
| With comorbidity | 28 | 40 |
| Without comorbidity | 42 | 60 |
Rate and frequency of clinical symptoms in CAUTI patients.
| Symptoms | Number of Patients ( | Percentage (%) |
|---|---|---|
| Only fever | 23 | 33 |
| Flank pain | 14 | 20 |
| Suprapubic pain | 8 | 11 |
| Fever; suprapubic pain | 6 | 9 |
| Dysuria | 7 | 10 |
| Urinary urgency | 9 | 13 |
| Hematuria | 3 | 4 |
| Confusion | 0 | 0 |
Month-wise distribution of bacterial isolates from CAUTI patients.
| Month | Isolate Number ( | Percentage (%) |
|---|---|---|
| January | 2 | 3 |
| February | 5 | 7 |
| March | 5 | 7 |
| April | 7 | 10 |
| May | 2 | 3 |
| June | 7 | 10 |
| July | 7 | 10 |
| August | 5 | 7 |
| September | 14 | 20 |
| October | 9 | 13 |
| November | 2 | 3 |
| December | 5 | 7 |
|
|
|
|
Figure 2Number of uropathogens from CAUTI patients during summer and winter.
Rate of bacterial species identified from CAUTI patients.
| Bacteria | CAUTI | Percentage (%) |
|---|---|---|
|
| 5 | 7 |
|
| 7 | 10 |
|
| 9 | 13 |
|
| 2 | 3 |
|
| 15 | 21 |
|
| 12 | 17 |
|
| 2 | 3 |
|
| 9 | 13 |
|
| 2 | 3 |
|
| 5 | 7 |
|
| 2 | 3 |
|
|
|
|
Antibiogram pattern of Klebsiella pneumoniae, the predominant isolate recovered from CAUTI patients.
| Antibiotics | Sensitive | Sensitivity % | Resistant | Resistance % |
|---|---|---|---|---|
| Amikacin (30 µg) | 15 | 100 | - | - |
| Cefepime (30 µg) | 10 | 66.7 | 5 | 33.4 |
| Colistin (10 µg) | 13 | 86.7 | 2 | 13.4 |
| Gentamicin (10 µg) | 13 | 86.7 | 2 | 13.4 |
| Ciprofloxacin (5 µg) | 8 | 53.4 | 7 | 46.7 |
| Levofloxacin (5 µg) | 10 | 66.7 | 5 | 33.4 |
| Meropenem (10 µg) | 10 | 66.7 | 5 | 33.4 |
| Ceftazidime (30 µg) | 8 | 53.4 | 7 | 46.7 |
| Ceftriaxone (30 µg) | 3 | 20 | 12 | 80 |
| Imipenem (10 µg) | 13 | 86.7 | 2 | 13.4 |
| Piperacillin/tazobactam (100/10 µg) | 10 | 66.7 | 5 | 33.4 |
| Teicoplanin (30 µg) | 8 | 53.4 | 7 | 46.7 |
| Cefoxitin (30 µg) | 13 | 86.7 | 2 | 13.4 |
| Nitrofurantoin (300 µg) | 5 | 33.4 | 10 | 66.7 |
| Ertapenem (10 µg) | 13 | 86.7 | 2 | 13.4 |
| Aztreonam (30 µg) | 5 | 33.4 | 10 | 66.7 |
| Amoxicillin/clavulanic acid (20/10 µg) | 8 | 53.4 | 7 | 46.7 |
| Sulfamethoxazole/trimethoprim (1.25/23.75 µg) | 10 | 66.7 | 5 | 33.4 |
| Mupirocin (200 µg) | 3 | 20 | 12 | 80 |
| Cefuroxime (30 µg) | 5 | 33.4 | 10 | 66.7 |
| Cephalothin (30 µg) | 5 | 33.4 | 10 | 66.7 |
| Tigecycline (15 µg) | 3 | 20 | 12 | 80 |
Antibiogram pattern of remaining bacterial isolates from CAUTI patients.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Amikacin (30 µg) | 5 | 7 | - | 10 | 9 |
| Cefepime (30 µg) | 5 | 5 | - | 2 | 9 |
| Colistin (10 µg) | 3 | 7 | - | 2 | 9 |
| Gentamycin (10 µg) | 5 | 7 | - | - | 7 |
| Ciprofloxacin (5 µg) | 3 | 5 | 5 | - | 9 |
| Levofloxacin (5 µg) | 5 | 5 | - | 2 | 5 |
| Meropenem (10 µg) | 5 | 7 | - | 6 | 5 |
| Ceftazidime (30 µg) | 5 | 5 | 2 | - | 9 |
| Ceftriaxone (30 µg) | 3 | - | - | - | 3 |
| Imipenem (10 µg) | 3 | 7 | - | - | 7 |
| Piperacillin/tazobactam (100 µg/10 µg) | 5 | - | - | 10 | 2 |
| Teicoplanin (30 µg) | - | 5 | 2 | - | 2 |
| Cefoxitin (30 µg) | 2 | 7 | - | 12 | 2 |
| Nitrofurantoin (300 µg) | - | 2 | 6 | 12 | - |
| Ertapenem (10 µg) | 3 | 7 | - | 10 | - |
| Aztreonam (30 µg) | 5 | 2 | - | - | 2 |
| Amoxicillin/clavulanic acid (20/10 µg) | - | 2 | 6 | 7 | - |
| Sulfamethox/trimethoprim (1.25/23.75 µg) | 5 | 5 | 6 | 2 | 2 |
| Daptomycin (30 µg) | - | - | 9 | 2 | - |
| Linezolid (30 µg) | - | - | 6 | 2 | - |
| Mupirocin (200 µg) | - | - | - | 5 | - |
| Tetracycline (30 µg) | - | - | 5 | 2 | - |
| Vancomycin (30 µg) | - | - | 7 | 2 | - |
| Erythromycin (15 µg) | - | - | - | 2 | - |
| Ampicillin (10 µg) | 2 | - | 7 | - | - |
| Moxifloxacin (5 µg) | - | - | 7 | - | - |
| Piperacillin/tazobactam (TZP) (36 µg) | - | - | - | 2 | 2 |
| Fusidic acid (10 µg) | - | - | 2 | - | - |
| Cefotaxime (30 µg) | 3 | - | - | - | - |
|
|
|
|
|
|
|
| Amikacin (30 µg) | 2 | 5 | - | 2 | - |
| Cefepime (30 µg) | 2 | - | - | 2 | - |
| Colistin (10 µg) | - | 3 | 2 | 2 | - |
| Gentamicin (10 µg) | - | 3 | 2 | 2 | - |
| Ciprofloxacin (5 µg) | - | 3 | - | 2 | - |
| Levofloxacin (5 µg) | - | - | - | 2 | - |
| Meropenem (10 µg) | - | - | - | 2 | - |
| Ceftazidime (30 µg) | 2 | - | - | 2 | - |
| Ceftriaxone (30 µg) | - | - | - | - | - |
| Imipenem (10 µg) | - | - | - | - | 2 |
| Pipiracillin/tazobactum (100/10 µg) | - | - | - | 2 | 2 |
| Teicoplanin (30 µg) | - | - | - | - | - |
| Cefoxitin (30 µg) | 2 | - | - | - | 2 |
| Nitrofurantoin (300 µg) | - | - | - | - | - |
| Ertapenem (10 µg) | 2 | - | - | 2 | 2 |
| Aztreonam (30 µg) | 2 | - | - | - | - |
| Amoxicillin/clavulanic acid (20/10 µg) | - | - | - | 2 | - |
| Sulfamethoxazole/trimethoprim (1.25/23.75 µg) | 2 | - | - | - | 2 |
| Cefuroxime (30 µg) | 2 | - | - | - | - |